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INTRODUCTION
The human gut microbiome, comprising up to 100
trillion microbes (microbiota) and their genomes [1,2],
functions symbiotically with the host superorganism it
inhabits. These unique populations of bacteria, viruses
and fungi are crucial not only for the innate maintenance
of health, but also in processing exogenous compounds
(medicines) intended to rectify homeostatic imbalances.
The realisation of this latter action of the microbiota has
altered the concept of pharmaceutical-microbiota inter-
actions, shifting the influencer role from medicines to an
appreciation of microbiome-medicine interplay. The mi-
crobiota, and in particular microbiome-encoded enzymes,
now represent plausible intermediate targets to alter drug
pharmacokinetics (absorption, distribution, metabolism
and elimination) to consequently enhance clinical re-
sponse.
The gut microbiota is not static, but rather is subject
to dynamic transformations as a consequence of; phar-
macological interventions (most notably antibiotic ther-
apy), pathology (gastroenteric and systemic infection),
nutritional status, circadian rhythm and environmental
influences [3,4]. inter-individual or intra-individual tem-
poral microbiota diversity or dysbiosis are thus of poten-
tial clinical significance, since microbe-mediated bioac-
tivation of prodrug formulations may vary.
Supplementation with “good” bacteria, that is, probiotics,
may accordingly unify or augment patient responses.
Conversely, microbial biotransformation may also gen-
erate bioinactive or toxic metabolites, such that strategies
to nullify the microbiome may be transiently beneficial.
Herein, this intriguing prospect of manipulating the mi-
crobiome to improve clinical patient outcomes is dis-
cussed with reference to the current literature.
IMPACT OF THE MICROBIOME ON DRUG
PHARMACOKINETICS AND THERAPEUTIC
OUTCOMES
Oral delivery of pharmaceuticals presents a multi-
tude of challenges, including an assurance of drug sta-
bility in the gastrointestinal lumen. implementation of
formulation strategies, such as enteric coating, have suc-
cessfully reduced the degradative effect of upper gas-
trointestinal pH. However, the contribution of the distally
increasing population of microbes to drug stability is fre-
*To whom all correspondence should be addressed: Cormac G.M. Gahan, c.gahan@ucc.ie.
†Abbreviations: Cgr, Cardiac Glycoside Reductase; CNS, Central Nervous System; CTLA-4, Cytotoxic T-Lymphocyte-Associated
protein 4; HMG-Co A, 3-Hydroxy-3-Methyl-Glutaryl-CoA; LDL-C, Low Density Lipoprotein Cholesterol; L-dopa, Levodopa; NSAID,
Non-Steroidal Anti-Inflammatory Drug.
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Mini-Review
The significance of the gut microbiota as a determinant of drug pharmacokinetics and accordingly thera-
peutic response is of increasing importance with the advent of modern medicines characterised by low solu-
bility and/or permeability, or modified-release. These physicochemical properties and release kinetics
prolong drug residence times within the gastrointestinal tract, wherein biotransformation by commensal mi-
crobes can occur. As the evidence base in support of this supplementary metabolic “organ” expands, novel
opportunities to engineer the microbiota for clinical benefit have emerged. This review provides an
overview of microbe-mediated alteration of drug pharmacokinetics, with particular emphasis on studies
demonstrating proof of concept in vivo. Additionally, recent advances in modulating the microbiota to im-
prove clinical response to therapeutics are explored.
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quently unappreciated. Previous reports suggested that the
relevance of the microbiota in dictating the pharmacoki-
netic profile of a drug is determined by its presentation to
the distal gut [5]. Therefore, traditionally, it has been ac-
cepted that the majority of drugs, which are absorbed from
the small intestine, will have little interaction with the mi-
crobiota unless they are candidates for sustained-release or
enterohepatic circulation. However, recent insights into
the impact of the small intestinal flora on mammalian
hosts [6] may lead to a paradigm shift in the considered
gastrointestinal sites of microbial biotransformation.
newly emerging drug candidates have a tendency toward
low solubility and/or permeability, properties which re-
sult in prolonged gastrointestinal residence times and
therefore a greater probability of microbial interactions. it
has thus become increasingly necessary to consider the
numerous metabolic processes coordinated by the micro-
biome, a selection of which are examined below and in
Figure 1 and Table 1.
Microbe-Mediated Prodrug Activation
The impact of the commensal (indigenous) micro-
biota on therapeutic drug efficacy has long been recog-
nised; for example, in the late 1930s the sulfa antibiotic
class were identified as substrates for microbial transfor-
mation [7]. The liberation of the active sulfanilamide
metabolite by gut bacteria, revealed that two genomes,
human and microbial, were implicated in the pharmaco-
logical response [7]. Preclinical studies in rats illustrated
that antibiotic administration could decrease the conver-
sion of the oral prodrug Prontosil to sulfanilamide [8] . On
this premise, it can be hypothesised that an interference in
human microbial metabolism, for instance with a course of
antibiotics, may diminish the therapeutic efficacy of cer-
tain co-administered medicines. Similarly, inter-individ-
ual variability in the composition of the gut microbiome
could potentially dictate the effectiveness of prodrug con-
version.
Sulfasalazine, indicated in ulcerative colitis, similarly
exploits azo-reductase enzymes secreted by colonic bac-
teria to generate sulfapyridine and 5-aminosalicylic acid,
an active anti-inflammatory moiety [9,10]. Conceivably,
changes in the intestinal microflora may therefore have
implications for sulfasalazine activation and ultimately re-
sponse. For example, Mikov et al. reported that probiotic
treatment significantly increased sulfasalazine reduction
in rat colon contents [11]. The gut microbiota can also be
favourably exploited to achieve site-specific drug release.
Recently, the co-administration of probiotics with a poly-
saccharide-based colon targeted formulation has been
shown, in rodent models of colitis, to ameliorate sul-
fasalazine efficacy [9].
Lovastatin, a lactone prodrug, has been shown to be
hydrolysed to its lipid-lowering β-hydroxy acid metabolite
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Figure 1. A summary of selected mechanisms by which the microbiota influences drug pharmacokinetics. Individual
panels correspond to the article text. 1.1 Agents including lovastatin or sulfasalazine are directly activated by the gut
microbiota. 1.2 The availability and uptake of drugs including simvastatin and amiodarone is influenced by the micro-
biota or by co-administration of probiotics through unknown mechanisms. 1.3 Toxicity of irinotecan is elevated by mi-
crobial β-glucuronidase activity and can be selectively inhibited by antibiotics or specific microbial β-glucuronidase
inhibitors. 1.4 Digoxin is inactivated in the gut by specific enzymatic activity associated with specific strains of Eg-
gerthella lenta (cgr+). 1.5 Paracetamol detoxification in the liver is competitively inhibited by the gut microbial metabo-
lite p-Cresol.
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Table 1. Impact of the intestinal microflora on drug pharmacokinetics. 
Drug
Amiodarone
Calcitonin
Diclofenac
Digoxin
Indomethacin
Insulin
Irinotecan
Ketoprofen
Levodopa
Loperamide
oxide
Lovastatin
Metronidazole
Pharmacotherapeutic
classification
Class III antiarrhythmic
Calciotropic hormone
Non-steroidal anti-
inflammatory drug
Cardiac glycoside
Non-steroidal anti-in-
flammatory drug
Anti-diabetic drug
Topoisomerase I 
inhibitor
Non-steroidal anti-
inflammatory drug
Anti-parkinson
Anti-propulsive
HMG-CoA-reductase
inhibitor
Anti-protozoal and anti-
bacterial
Effect of the gut 
microbiota on drug
pharmacokinetics
↑ absorption
↑ metabolism 
(proteolysis)
↑ metabolism
(deglucuronidation) and
delayed excretion
↑ metabolism (reduction)
↑ metabolism
(deglucuronidation) and
delayed excretion
↑ metabolism 
(proteolysis)
↑ metabolism 
(deglucuronidation) and
delayed excretion
↑ metabolism
(deglucuronidation) and
delayed excretion
1. ↓ absorption
2. ↑ metabolism 
(dehydroxylation)
↑ metabolism (reduction)
↑ metabolism 
(hydrolysis)
↑ metabolism (reduction)
Implicated microbe
or microbial enzyme
(if known)
Escherichia coli Nissle
1917
β-glucuronidase en-
zymes
Eggerthella lenta
β-glucuronidase en-
zymes
Protease enzymes
β-glucuronidase 
enzymes produced by
bacteria, including 
Escherichia coli, Bac-
teroides vulgatus and
Clostridium ramosum 
β-glucuronidase en-
zymes
1. Helicobacter pylori
Postulated effect of
the gut microbiota
on drug 
bioavailability
(F)/activity/toxicity
↑ F
↓ F and activity
↑ toxicity (enterohep-
atic circulation)
↓ F and cardiac re-
sponse
↑ toxicity (enterohep-
atic circulation)
↓ F and activity
↑ toxicity (regenera-
tion of active SN-38
within the intestinal
lumen)
↑ toxicity (enterohep-
atic circulation)
↓ F and activity
↑ activity (prodrug 
activation)
↑ F of active β-hy-
droxy acid metabo-
lite, therefore,
potentially ↑ pharma-
cological effect
↑ toxicity
Ref
[13]
[42]
[16]
[18]
[19]
[20]
[16]
[42]
[14]
[16]
1.[36]
[37]
[38]
[39] 
2.[35]
[43]
[12]
[44]
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Table 1 (cont’d). Impact of the intestinal microflora on drug pharmacokinetics. 
Drug
Nitrazepam
Nizatidine
Olsalazine
Paracetamol
Prontosil
Ranitidine
Risperidone
Sulfasalazine
Zonisamide 
Pharmacotherapeutic
classification
Benzodiazepine
H2-receptor antagonist
Aminosalicylate
Analgesic and 
antipyretic
Sulfa drug
H2-receptor antagonist
Antipsychotic 
Aminosalicylate 
Antiepileptic
Effect of the gut 
microbiota on drug 
pharmacokinetics
↑ metabolism 
(nitroreduction)
↑ metabolism (cleavage
of N-oxide bond)
↑ metabolism
(reduction)
↓ metabolism
(p-Cresol-mediated
competitive sulfonation)
↑ metabolism
(reduction)
↑ metabolism (cleavage
of N-oxide bond)
↑ metabolism
(scission of the 
isoxazole ring)
↑ metabolism
(reduction)
↑ metabolism
(reduction)
Implicated microbe
or microbial enzyme
(if known)
Nitroreductase 
enzymes
Azoreductase 
enzymes
Clostridium difficile
and others 
Azoreductase 
enzymes
Azoreductase 
enzymes
Clostridium 
sporogenes
Bifidobacterium 
bifidum 
Bacteroides vulgatus
Escherichia coli
Salmonella 
typhimurium
Pseudomonas 
fluorescens
Lactobacillus 
rhamnosus
Streptococcus faecalis
Postulated effect of
the gut microbiota
on drug 
bioavailability
(F)/activity/toxicity
↑ toxicity (postulated
association with 
nitrazepam-induced
teratogenicity in rats)
↓ systemic F
↑ activity (prodrug 
activation)
↑ risk of 
hepatotoxicity
↑ activity (prodrug 
activation)
↓ systemic F
↑ activity due to liber-
ation of active 5-
aminosalicyclic acid.
Also, potentially ↑
toxicity due to en-
hanced generation of
sulfapyridine, which
can be systemically
absorbed
Ref
[45]
[46]
[47]
[21]
[8]
[46]
[48]
[10]
[49]
when incubated with human and rat fecalase (enzyme
fraction of feces), indicating microbe-directed metabolism
[12]. Further to this, antibiotic treatment reduced systemic
exposure to β-hydroxy acid by 35 to 50 percent following
oral lovastatin administration to rats. Chronic antibiotic
usage in the clinic may thus put patients at risk of thera-
peutic inefficacy should this effect prove translational.
Microbe-Mediated Alteration of Drug Absorption
Concomitant administration of the probiotic bac-
terium Escherichia coli nissle 1917 has been demon-
strated to increase the bioavailability of amiodarone, a
vaughan-williams class iii antiarrhythmic, in rats [13].
Matuskova et al. propose that the observed 43 percent in-
creased bioavailability may be due to a reduction in intes-
tinal pH, facilitating enhanced ionisation of the molecule
and consequently mucosal transit. Alternatively, it is the-
orised that the heighted uptake could be attributed to up-
regulated expression of the influx transporter OATP2B1
[13].
Microbe-Mediated Deconjugation: 
Enterohepatic Circulation of Drugs
Microbiota-mediated xenobiotic metabolism can also
adversely affect host outcomes, limiting the clinical ap-
plicability of drug candidates. identification of the micro-
bial mechanisms that are responsible has the potential to
lead to precise interventions to eliminate the activity and
improve drug tolerability.
irinotecan, an intravenous prodrug formulation of the
antineoplastic topoisomerase i inhibitor Sn-38, is associ-
ated with delayed diarrhea. This dose-limiting gastroin-
testinal toxicity arises through the intra-luminal
regeneration of Sn-38 from its hepatic-derived, non-toxic
glucuronide metabolite Sn-38G. The deglucuronidation
activity and resultant toxicity is attributed to microbial β-
glucuronidases [14]. interventions to reduce toxic side ef-
fects have thus focused on suppressing β-glucuronidase,
initially, through broad-spectrum antibiotic therapy and,
more recently, with selective microbial β-glucuronidase
inhibitors [14,15]. Mitigation of Sn-38-mediated toxicity
is the epitome of advantageous modulation of the micro-
biome to advance patient outcomes, and interestingly ex-
tends the scope of this therapeutic strategy to intravenous,
as well as oral medicines.
The extended applicability of small molecule in-
hibitors of microbial β-glucuronidase to improve pharma-
ceutical tolerability has been examined with non-steroidal
anti-inflammatory drugs (nSAiDs†). The enteropathic ad-
verse reactions associated with this commonly prescribed
class are, like Sn-38, related to the hepatobiliary transit
of glucuronides, followed by enterohepatic circulation of
microbial recovered aglycones [16]. Murine models have
demonstrated that small intestinal insults arising from pro-
tracted exposure to carboxylic acid-bearing nSAiDs (di-
clofenac, indomethacin, ketoprofen) can be prevented by
selective blockade of microbial β-glucuronidase activity
[16]. A subsequent study by Liang et al. advances this ev-
idence base with pharmacokinetic confirmation that per-
turbation of the microbiota can influence indomethacin
metabolism and correspondingly enteropathy. Antibiotic-
driven β-glucuronidase depletion resulted in reduced re-
absorption of indomethacin, as exemplified by accelerated
elimination and a shortened half-life in mice [17], which
may explain the diminished enteropathy reported by Saitta
et al. [16]. it was also shown that indomethacin recipro-
cally alters the microbiota, which could have ramifications
for patient health [17]. whilst there is presently a paucity
of data to support the translation of these findings to the
clinical setting, this research provides further impetus to
alter the microbiota in the clinic.
Microbe-Mediated Drug Inactivation
Digoxin, a cardiac glycoside used in the treatment of
congestive heart failure and atrial fibrillation, has a nar-
row therapeutic index, meaning that modest changes in
bioavailability can induce toxicity. in the 1980s, re-
searchers discovered that Eggerthella lenta, an anaerobic
colonic bacterium, possessed the capacity to inactivate
digoxin [18]. Decades later, it was shown that whilst
colonisation with E. lenta is fundamental to digoxin inac-
tivation, only a proportion of individuals harboring the
bacterium will inactivate the drug. This disparity in mi-
crobial metabolic activity was determined to be a strain-
specific effect with only some strains of E. lenta
possessing the “cardiac glycoside reductase” (cgr) operon,
which is responsible for inactivation of digoxin [19]. in
patients that carry cgr+ E. lenta, a routine antibiotic regi-
men may temporarily abolish the generation of dihy-
drodigoxin, the inactive metabolite, and concomitantly
increase digoxin serum levels compared to pre-antibiotic
baseline [20]. in the absence of antibiotic intervention
these patients may be at risk of exhibiting reduced drug
efficacy. Dietary modulation also represents a strategy to
suppress cgr operon expression and consequently digoxin
inactivation [19].
Microbe-Mediated Alteration of Host Drug 
Metabolism
The gut microbiota is additionally indirectly impli-
cated in drug metabolism. inter-individual variability in
the processing of paracetamol (acetaminophen), an anal-
gesic and antipyretic, has been shown to be correlated with
the endogenous microbial metabolite p-Cresol [21]. Parac-
etamol is predominantly metabolised in the liver via two
phase ii pathways, glucuronidation and sulfation. p-Cresol
and paracetamol are both substrates for hepatic sulfo-
transferases, and therefore high baseline p-Cresol levels
are postulated to decrease paracetamol metabolism
through competitive sulfonation. Patients harbouring an
abundance of p-Cresol are thus expected to be at elevated
risk of hepatotoxicity [21].
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EMERGING INSIGHTS INTO THE COMPLEX
ROLE OF BACTERIA IN INFLUENCING 
CLINICAL OUTCOMES
Antineoplastic Medicines
Recently, the impact of the intestinal microflora on
the immunomodulatory effect of chemotherapeutics has
been uncovered. Sivan et al. observed improved tumor
control in mice with a combination of Bifidobacterium and
anti-PD-L1 monoclonal antibody therapy compared to the
immunotherapeutic intervention alone [22]. On this basis,
the authors concluded that the commensal microbiota
could be regulated for clinical benefit, and postulated that
the approach could be extended to other cancer im-
munotherapies.
Cyclophosphamide, an alkylating agent, provokes im-
munogenic apoptosis of cancer cells, overturning im-
munosuppressive T cells and promoting TH1 and TH17
cellular responses [23]. viaud et al. established that cy-
clophosphamide changes the composition of the murine
small intestinal microbiota and elicits the translocation of
specific Gram-positive bacterial species to peripheral lym-
phoid organs, wherein a “pathogenic” subset of T helper
17 (pTH17) cells and memory TH1 cells are resultantly
generated [23]. Tumors of germ-free or antibiotic-treated
mice were resistant to cyclophosphamide, an effect at-
tributed to reduced pTH17 responses [23].
vétizou et al. similarly demonstrated that the tumor
response to ipilimumab, a human monoclonal antibody
targeting CTLA-4 (a negative regulator of T cell activa-
tion), is reliant on specific Bacteroides species [24].
Germ-free and antibiotic-treated mice were non-respon-
sive to ipilimumab, an adverse outcome that was over-
turned by B. fragilis gavage, inoculation with B. fragilis
polysaccharides, or by adoptive immunotherapy with B.
fragilis-specific murine T cells [24]. Transplantation of
Bacteroides-containing feces from patients with metasta-
tic melanoma likewise restored murine CTLA-4 blockade.
Lehouritis et al. hypothesise that tumor-associated
bacteria may influence chemotherapeutic drug efficacy,
resistance or off-target toxicity on the basis of in vitro and
murine data [25]. Thirty chemotherapeutic agents were
subjected to an in vitro MTS cell cytotoxicity assay, which
identified 10 drugs with reduced efficacy and six drugs
with enhanced efficacy in combination with bacteria. For
instance, the cytotoxicity of gemcitabine was negated by
bacteria, a finding that translated in vivo. Conversely,
CB1954 was shown to be activated by bacteria both in
vitro and in vivo. Bacterial co-localisation with a tumor
due to gut translocation or infection could therefore result
in the off-target bioactivation and toxicity of certain
chemotherapeutics. However, specific manipulation of
intra-tumoral bacteria could enhance the cytotoxicity of
these same agents by modulating biotransformation in
situ.
These pre-clinical studies, if translational, highlight
the potentially serious implications of microbial distur-
bance, inflicted by antibiotic co-prescribing, bacterial
translocation or infection, on certain cancer therapies. Fur-
thermore, this data underscores the potential therapeutic
benefit of microbiome-modulating interventions for en-
hancing chemotherapeutic efficacy.
Cardiovascular Medicines
Statins, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) reductase inhibitors, are commonly prescribed for
dyslipidemia, lowering low-density lipoprotein cholesterol
(LDL-C) levels by up to 55 percent [26,27]. Despite the
acknowledged effectiveness of statin therapy in the pro-
phylaxis and management of cardiovascular disease, inter-
individual variability in response exists [27,28].
Kaddurah-Daouk et al. noted, through metabolomics, that
increased simvastatin plasma concentrations correlated
with higher pre-treatment levels of microbially synthe-
sised secondary bile acids [29]. This implies that the mi-
crobiota are possibly involved in determining simvastatin
bioavailability. Furthermore, this research elucidated a
link between higher baseline levels of coprostanol, a re-
duced bacterial metabolite of endogenous cholesterol, and
simvastatin response. interestingly, administration of Lac-
tobacillae bacterial strains capable of converting choles-
terol to coprostanol have been proposed as a probiotic
lipid-lowering approach [29,30]. As previously discussed,
Yoo et al. recently concluded that the gut microbiota in-
fluences lovastatin pharmacokinetics [12]. These findings
suggest that patients receiving long term antibiotic ther-
apy may fail to respond adequately to statins, posing an
increased risk of serious cardiovascular sequelae.
Central Nervous System Active Medicines
Olanzapine, an atypical antipsychotic, is associated
with a myriad of adverse metabolic effects including
weight gain and insulin tolerance [31]. Clinically signifi-
cant increases in body mass are observed in approximately
one-third of olanzapine treated patients, a predisposing
factor for the development of metabolic syndrome, co-
morbid diseases such as type 2 diabetes mellitus, and poor
compliance with medication regimens [31,32]. Consider-
ing the established link between human obesity and the
gut microflora [33], as well as preclinical studies sugges-
tive of olanzapine-induced fecal microbiota alteration
[34], Davey et al. investigated the hypothesis that the gut
microbiota may be responsible for some of olanzapine’s
metabolic effects. it was determined that decimation of
the rat microbiota with broad-spectrum antibiotics dimin-
ished olanzapine-induced metabolic dysfunction [32].
Harnessing probiotics or prebiotics to prevent microflora
shifts may thus constitute a novel approach to successively
enhance olanzapine’s side effect profile, medication ad-
herence rate and therapeutic response.
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Levodopa (L-dopa), a dopamine precursor used in the
treatment of Parkinson’s disease, must partition the blood-
brain barrier and undergo decarboxylation within the cen-
tral nervous system (CnS) in order to exert its
dopaminergic therapeutic effect. incubation of levodopa
with rat cecal contents revealed a gut microbial dehy-
droxylation process yielding m-tyramine and m-hydrox-
yphenylacetic acid metabolites [35] , which could translate
as decreased bioavailable levodopa. infection with the
gastric pathogen Helicobacter pylori is more prevalent
amongst patients with Parkinson’s disease compared to
healthy controls. Several studies have illustrated a causal
relationship between H. pylori infection and dampened
levodopa responses, proposing decreased absorption as
the underpinning effect [36-39]. H. pylori screening and
eradication regimens (antibiotics and proton-pump in-
hibitors) thus represent a potential strategy to optimize
levodopa doses and clinical effect.
Immunosuppressant Medicines
Tacrolimus, a calcineurin inhibitor used in the pro-
phylaxis of transplant rejection, has a narrow therapeutic
index [40]. elucidating the mechanisms influencing drug
concentrations at the extremes of the therapeutic range is
hence of interest from the perspectives of treatment re-
sponse and patient safety. Lee et al. hypothesised that the
gut microbiota dictate tacrolimus dosing requirements
since post-transplant diarrhea and enterocolitis, as well as
antibiotic use have previously been correlated with altered
trough levels of the drug [41]. in a pilot study of 19 trans-
plant recipients, the levels of fecal carriage of Faecal-
ibacterium prausnitzii in the week immediately after
transplantation, was greater in patients subsequently re-
quiring a 50 percent dosage escalation in the first month
of treatment [41]. whilst the precise manner in which F.
prausnitzii impacts tacrolimus pharmacokinetics was not
examined, this study may serve to explain inter-patient
variability in therapeutic tacrolimus dosages.
CONCLUSION
in addition to the metabolic capability of enterocytes
and hepatocytes, it is now increasingly accepted that the
gut microbiota influences drug pharmacokinetics and cor-
respondingly bioavailability, efficacy or adverse effects.
Modulating the microbiome, either through exogenous re-
placement (probiotics) or curtailing interventions, such as
antibiotics or specific inhibitors, affords exciting oppor-
tunities to improve healthcare outcomes and advance per-
sonalised medicine. The contribution of the gut
microbiome to drug pharmacokinetic determination
should therefore now be reflected in the drug development
process so that more efficacious and tolerable medicines
ensue.
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